Van Oekelen O, Nath K, Mouhieddine TH, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023;141(7):756-765. Open Access

On page 756, in the second Key Point, the response rate of 91.4% should be 62.9%.

Under “Salvage with T-cell–engaging therapies after CAR T is feasible and can lead to durable responses,” on pages 760-761, “The ORR for T-cell–engaging therapies at any point after CAR T relapse was 91.4% (32/35 evaluable instances)” should read “The ORR for T-cell–engaging therapies at any point after CAR T relapse was 62.9% (22/35 evaluable instances).”